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Background: Since 2003, the United States National Institutes of Health (NIH) has sought to restructure the clinical
research enterprise in the United States by promoting collaborative research partnerships between academically-
based investigators and community-based physicians. By increasing community-based provider participation in
research (CBPPR), the NIH seeks to advance the science of discovery by conducting research in clinical settings
where most people get their care, and accelerate the translation of research results into everyday clinical practice.
Although CBPPR is seen as a promising strategy for promoting the use of evidence-based clinical services in
community practice settings, few empirical studies have examined the organizational factors that facilitate or hinder
the implementation of CBPPR. The purpose of this study is to explore the organizational start-up and early
implementation of CBPPR in community-based practice.
Methods: We used longitudinal, case study research methods and an organizational model of innovation
implementation to theoretically guide our study. Our sample consisted of three community practice settings that
recently joined the National Cancer Institute’s (NCI) Community Clinical Oncology Program (CCOP) in the United
States. Data were gathered through site visits, telephone interviews, and archival documents from January 2008 to
May 2011.
Results: The organizational model for innovation implementation was useful in identifying and investigating the
organizational factors influencing start-up and early implementation of CBPPR in CCOP organizations. In general, the
three CCOP organizations varied in the extent to which they achieved consistency in CBPPR over time and across
physicians. All three CCOP organizations demonstrated mixed levels of organizational readiness for change. Hospital
management support and resource availability were limited across CCOP organizations early on, although they
improved in one CCOP organization. As a result of weak IPPs, all three CCOPs created a weak implementation
climate. Patient accrual became concentrated over time among those groups of physicians for whom CBPPR
exhibited a strong innovation-values fit. Several external factors influenced innovation use, complicating and
enriching our intra-organizational model of innovation implementation.
Conclusion: Our results contribute to the limited body of research on the implementation of CBPPR. They inform
policy discussions about increasing and sustaining community clinician involvement in clinical research and expand
on theory about organizational determinants of implementation effectiveness.
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In 2003, the United States National Institutes of Health
(NIH) embarked on a fundamental restructuring of the
national clinical research enterprise [1]. The centerpiece
of its Roadmap for Medical Research has been the intent
to create collaborative partnerships between academically-
based investigators and community-based physicians to
conduct clinical research on a sustained basis [2]. By
increasing community-based provider participation in re-
search (CBPPR) through Clinical and Translation Science
Awards, federally funded provider-based research net-
works, and other mechanisms, the NIH has sought to
advance the science of discovery by conducting research
in clinical settings where most people get their care, and
accelerate the translation of research results into everyday
clinical practice [1-6]. The Roadmap has spurred discus-
sion of the potential benefits of CBPPR [6-8], infrastruc-
ture and workforce training needs for CBPPR [4,9],
common barriers to increasing CBPPR [7,10,11], and strat-
egies for overcoming those barriers [7,10].
Missing from this discussion, though, is an empirical in-
vestigation of the organizational factors that facilitate or
hinder the implementation of CBPPR. For community
practice settings, CBPPR is a complex innovation whose
implementation requires systemic organizational changes
in staffing, workflow, information systems, and reward
structures. Even with substantial external assistance, com-
munity practice settings may find it challenging to create a
supportive organizational context and culture for CBPPR.
This task may be especially challenging when community
practice settings first become involved in clinical research.
Effective implementation of CBPPR during start-up and the
early implementation phase, however, may provide a critical
pathway for sustained community physician engagement in
clinical research.
In this study, we examine the organizational start-up
and early implementation of CBPPR in community prac-
tice settings. Using case study research methods and im-
plementation theory, we identify the organizational factorsImplementation 
Policies and 
Practices 
Management 
Support 
Resource 
Availability 
Organizational 
Readiness for 
Change  
Figure 1 Organizational model of innovation implementation.associated with the effective implementation of CBPPR in
three community practice settings that joined the National
Cancer Institute’s (NCI) Community Clinical Oncology
Program (CCOP) in the United States, a federally funded
provider-based research network with a 28-year history of
translating research into practice [12]. Our results contrib-
ute to theory about organizational determinants of imple-
mentation effectiveness and inform policy discussions
about increasing and sustaining community clinician
involvement in clinical research.
Methods
Conceptual framework
We regarded CBPPR as an innovation and employed an
organizational model of innovation implementation to
guide our study (Figure 1). Briefly, the model posits that
consistent, high-quality innovation use (implementation ef-
fectiveness) is a function of the organization’s readiness for
change, the level of management support and resources
available, the implementation policies and practices (IPPs)
that the organization puts into place, the climate for imple-
mentation that results from these policies and practices,
and the extent to which intended users of the innovation
perceive that innovation use fosters the fulfillment of their
values.
Organizational readiness for change (ORC) is a pre-
implementation phase construct that refers to
organizational members’ collective confidence to imple-
ment change and collective commitment to pursue
courses of action that will lead to successful change [13].
Organizational readiness sets the stage for implementa-
tion and affects innovation use through other constructs
in the model.
Management support and resource availability are two
implementation-phase constructs that shape the
organizational context of implementation [14-16]. Man-
agement support is critical because managers set
organizational priorities and control resources needed in
implementation. If management supports exists andImplementation 
Climate 
Innovation-
Values Fit 
Implementation 
Effectiveness 
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into place more, high-quality policies and practices to
promote innovation use [15].
IPPs refer to the plans, practices, structures, and strat-
egies that organizations employ to promote innovation
use [15,17]. When IPPs allow organizational members to
incorporate the innovation with a significant level of op-
erational, cultural, and strategic fit, there is an increased
chance for effective implementation of the innovation.
Effective implementation can be achieved through differ-
ent combinations of policies and practices [16,17]. The
collective effect of these policies and practices shape the
optimum climate to implement consistent, high-quality
innovation use.
Implementation climate refers to organizational mem-
bers’ shared perception that innovation use is expected,
supported, and rewarded [17,18]. Implementation cli-
mate emerges from organizational members’ shared
experiences with, observations of, and discussions about
the organization’s IPPs. Organizations create a positive
climate for implementation by employing a variety of
mutually reinforcing policies and practices to enhance
organizational members’ means, motives, and opportun-
ity for innovation use.
Innovation-values fit (IVF) refers to the extent to
which organizational members perceive that innovation
use will foster the fulfillment of their values [17]. Al-
though individuals may vary in their values, emphasis
here is given to values shared by groups (e.g., oncologists
in group-practice). IVF is held to moderate the relation-
ship of implementation climate and implementation
effectiveness. Even in a strong implementation climate,
innovation use can range from non-use to compliant use
to committed use depending on IVF.
Study setting
Established in 1983, the CCOP is a three-way partnership
involving the NCI’s Division of Cancer Prevention (NCI/
DCP), selected cancer centers and clinical cooperative
groups (CCOP research bases), and community-based net-
works of hospitals and physician practices (CCOP organiza-
tions) (Figure 2) [12]. NCI/DCP provides overall direction
and funding for community hospitals and physician prac-
tices to participate in clinical trials; CCOP research bases
design clinical trials; and CCOP organizations assist with
patient accruals, data collection, and dissemination of study
findings. As of December 2010, 47 CCOP organizations
located in 28 states, the District of Columbia, and Puerto
Rico participated in NCI-sponsored clinical trials. The
CCOP includes 400 hospitals and more than 3,520 commu-
nity physicians.
In FY 2010, the CCOP budget totaled $93.6 million.
The median CCOP organization award was $850,000.
NCI funds CCOP organizations through a cooperativeagreement whereby participating organizations are
expected to share the costs with NCI. Continued
funding depends on the performance of the CCOP
organization in meeting clinical trial enrollment goals
(i.e., accrual) set by NCI. CCOP organizations are
required to accrue patients in both cancer treatment and
cancer prevention and control (CP/C) clinical trials.
Cancer treatment clinical trials refer to the evaluation of
cancer therapies that generally fall into one of three cat-
egories: medical, surgical, or radiation oncology. CP/C
clinical trials refer to evaluation of new methods of
detecting cancer risk and preventing primary and sec-
ondary cancers. It also refers to the evaluation of symp-
tom management, rehabilitation, and continuing care
interventions designed to minimize the burden of cancer
and improve quality of life. The NCI establishes accrual
goals for cancer treatment and CP/C clinical trials based
on the CCOP’s past accrual performance and expected
accrual performance given the available menu of NCI-
sponsored clinical trials.
CCOP organizations are led by a physician Principal
Investigator (PI) who provides local program leadership
[12]. CCOP staff members typically include an associate
PI, a program administrator, research nurses or clinical
research associates, data managers, and regulatory spe-
cialists. These staff members coordinate the review and
selection of new clinical trial protocols for CCOP
participation, disseminate protocol updates to the par-
ticipating physicians, and collect and submit study data.
CCOP-affiliated physicians accrue or refer participants
to clinical trials, and typically include medical, surgical
and radiation oncologists, general surgeons, urologists,
gastroenterologists, and primary care physicians. CCOP-
affiliated physicians, through their membership in CCOP
research bases, also participate in the development of
clinical trials by proposing study ideas, providing input
on study design, and occasionally, serving in the role of
PI or co-PI for a clinical trial.
Study design
The study followed a hypothetico-deductive approach to
qualitative research and used a longitudinal, multiple
case study design with the CCOP organization as the
unit of analysis. Case study methods are well-suited for
studying implementation processes, which tend to be
fluid, non-linear, and context-sensitive [19-22]. In
addition to permitting in-depth analysis of individual
cases, case study methods offer analytic strategies for
systematically comparing patterns observed across cases
[21,22]. Our sample consisted of three CCOP organiza-
tions that are located in the Midwest that received initial
CCOP funding between 2002 and 2005. Table 1 shows
the characteristics of each of the three CCOP organiza-
tions upon inception of the program. An in-depth study
Figure 2 The National Cancer Institute’s community clinical oncology program. Adapted from: Kaluzny AD, Morrissey JP, McKinney MM.
Emerging organizational networks: the case of the Community Clinical Oncology Program. In SS Mick and Associates, Innovations in Health Care
Delivery: Insights for Organization Theory. San Francisco: Jossey-Bass, 1990.
Teal et al. Implementation Science 2012, 7:41 Page 4 of 15
http://www.implementationscience.com/content/7/1/41of these three CCOPs allowed us to explore the
organizational factors that facilitate or hinder the start
up and early implementation of CBPPR in community
practice settings. The Institutional Review Board (IRB)
at the University of North Carolina at Chapel Hill
approved this study.
Data collection procedures
Data were gathered through site visits, telephone inter-
views, and archival documents from January 2008 to May
2011. A two-person research team visited each CCOP
organization between January 2008 and April 2008. During
the site visit, the team conducted 47 individual and group
interviews with CCOP leaders, CCOP physicians and staff,
and hospital managers. In subsequent years, the team inter-
viewed the CCOP PI and CCOP administrator from each
CCOP organization separately by telephone to gather data
about implementation processes, facilitators, barriers, chal-
lenges, and opportunities. Table 2 shows the breakdown of
interview participants by CCOP organization over time.
Each year, the team developed semi-structured interview
guides to conduct the interviews, audio-recorded the inter-
views, and transcribed them verbatim.Table 1 Characteristics of the CCOP Organizations in Their Fir
CCOP
Site
First Year
of CCOP
funding
Number
of Performance
Sites
Number of
Accruing
Physiciansa
A 2002 3 11
B 2005 7 10
C 2002 2 29
Source: CCOP organizations’ first submitted CCOP progress report.
Note: a. Includes physicians who enrolled at least 1 patient on a treatment and/or C
b. Does not include the PI, co-PI, or CCOP Administrator.In addition, the research team obtained data from CCOP
annual progress reports and grant applications. The NCI
requires that CCOP organizations file annual progress
reports and periodic re-applications for funding. These
documents included detailed data on the CCOP organiza-
tion’s structure, operations, and accrual data for each treat-
ment and CP/C clinical trial, sorted by CCOP research
base, accruing hospital, and accruing physician.
Analysis
Data analysis involved three phases: data coding, within-
case analysis, and between-case analysis. In the first
phase, we used qualitative data analysis software,
ATLAS.ti 5.0 (and later 6.0), to code the study data. The
conceptual framework provided a starting list of codes,
which we supplemented with emergent codes as analysis
proceeded. Using a common codebook, two investigators
(BW, DB) conducted a pilot test by independently cod-
ing four transcripts. They then fine-tuned the coding
manual’s definitions, decision rules, and examples. Two
other research team members (MJ, RT) coded the
remaining documents and an investigator (DB) reviewed
the coding for accuracy and consistency. The researchst Year of Operation
Number of
CCOP Funded
Research Staff
FTEsb
Number of
NCI-research
base affiliates
Number of
Newly Diagnosed
Cancer Patients
3.7 4 1474
7.2 4 2470
9.3 4 4115
P/C trial.
Table 2 Number and Type of Interview Participants per CCOP Organization, 2008 to 2011
Site 2008 (Yr 1) 2009 (Yr. 2) 2010 (Yr. 3) 2011 (Yr. 4)
CCOP A Number 17 5 2 2
Type CCOP PI CCOP PI CCOP PI CCOP PI
CCOP Admin CCOP Admin CCOP Admin CCOP Admin
2 hospital admin 1 hospital admin
6 physicians 2 physicians
7 CRAs/support staff*
CCOP B Number 11 6 2 2
Type CCOP PI CCOP PI CCOP PI CCOP PI
CCOP Admin CCOP Admin CCOP Admin CCOP Admin
1 hospital admin 2 hospital admin
4 physicians 4CRAs/support staff* 1 physician
1 research nurse
CCOP C Number 19 6 2 2
Type CCOP P I CCOP PI CCOP PI CCOP PI
CCOP Admin CCOP Admin CCOP Admin CCOP Admin
3 hospital admin 1 hospital admin
2 physicians 3 physicians
12 CRAs/support staff*
* Each site visit included a group interview with clinical research associates (CRAs) and CCOP support staff managing IRB and regulatory issues.
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compiled from the three CCOP organizations.
Due to wide variation in the formatting of progress
reports and grant applications across the three CCOP
organizations, we could not assign these documents to
ATLAS.ti. Instead, we extracted numerical data from
these documents (e.g., patient accrual figures for individ-
ual physicians) and used reported information to
triangulate the results of this study. Over 500 pages of
progress reports and grant applications were reviewed.
In the second phase, we conducted a within-case
analysis of each CCOP organization. We generated sum-
mary reports of each code for each CCOP site in Year 1
through Year 3 of the study. We assessed the degree to
which the construct emerged in the data (its ‘salience’)
and the degree to which relationships among constructs
were consistent with the hypothesized model. Salience
in this study refers to the frequency with which con-
structs (or corresponding codes) appeared in the data
and does not necessarily indicate the importance of the
construct within the conceptual model [23,24]. For
example, the implementation effectiveness construct
appeared as a code 39 times in CCOP A interview tran-
scripts, 49 times in CCOP B, and 46 times in CCOP C
(Table 3).
In the third phase, we applied the same criteria across
the cases to determine if cross-case variation in imple-
mentation was consistent with the hypothesizedrelationships in the model. We generated 12 meta-
reports that summarized each code across all three sites
from Year 1 through Year 3 of the study. Over 120 sum-
mary reports were generated from coded text segments.
Results
The organizational model for innovation implementation
depicted in Figure 1 proved useful for identifying and in-
vestigating the organizational factors that facilitated and
hindered start-up and early implementation of CBPPR in
CCOP organizations. Generally speaking, the model’s
constructs were salient in the data (Table 3) and the
observed relationships among constructs fit the model.
Some constructs exhibited less salience than others, as
measured by the number of text units coded for that
construct, either because interview questions pertinent
to that construct were asked only in specific years (e.g.,
organizational readiness for change) or because inter-
view participants had less to say about the issue (e.g.,
management support) or because the construct proved
difficult to identify in the natural language responses of
interview participants (e.g., IVF). Each year, we asked
many questions and heard a great deal about the
operational aspects of CBPPR implementation. Not sur-
prisingly, IPP was the most salient construct in our data.
Briefly, results can be summarized as follows. The three
CCOP organizations varied in the extent to which they
achieved consistency in CBPPR over time and across
Table 3 Occurrence of each coded text unit from interviews conducted between 2008 to 2011
Code Total
text units
across sites
Illustrative quote
CCOP
A
CCOP
B
CCOP
C
Implementation
Effectiveness
39 49 46 134 So far during this current grant period they’ve only
put 11 patients on and they were pretty good about
putting about one-third of the patients for the program
overall on. So they were good for 30 or 35 [patients].
Organizational
Readiness for
Change*
44 36 32 112 I had the feeling that they were fairly confident, not
overwhelmingly confident but fairly confident that
they’d be able to do it [make the minimum
requirements to become a CCOP].
Management Support 79 54 55 188 Well, we were doing the research and I don’t
know if they [hospital management] still know
exactly what the CCOP is. They know it’s a grant
for our research program. I don’t think there’s a
lot of understanding at exactly how much that
the research staff does.
Resources
Available
97 95 68 260 We’re having problems with the trials. We are
not—and across the board, the physicians
from different areas—the Rad Onc physicians
are saying we just don’t have the RTOG trials that
we need to be able to work with you all.
Implementation
Policies &
Practices
221 228 237 686 . . .so we'll see a patient, say we have somebody
hat comes in adjuvant colon cancer, and then they
potentially could be eligible for N0147. Then we’ll put
the information in the chart for the physician with
our card and the consent. . .then we’ll put the guts
of the protocol, like the schema and the treatment
plan, eligibility in the calendar, and then I have a—what
we call pink sheet. It’s a communication sheet that
we’ll write out for the physician, and we’ll tell him this is
what it looks like this patient might be eligible for, and
these are the tests needed, and there’s the consent.
Implementation Climate 96 65 83 244 I don’t feel the Rad Oncs are as committed to it, for
whatever reason, and it may be because of the way
they’re set up and the way they do their work, and it
may be set up because of the way their administration is,
because we’re a private group. I don’t know for whatever
reason why. There's no financial incentive to do it, but I
just don’t feel that they’re into it as much.
Innovation-
Values Fit
51 45 43 139 I think they [physicians] all want to do research. I think they
all want to get their patients the highest level of care. I
think that in order to participate with the studies that that’s
what they’re doing. So they’re looking for the best way to
serve their patients, as well as helping with the hospital.
External
Factors
121 137 120 378 It [economic downturn] has had more of an impact than
I would have thought. I was probably naïve about that
but patients are much more concerned about their co-pays
and about what additional charges they might be facing for
things that most of us would consider mundane visits like
the infusion room charge when they’re here getting a free
drug on a research study. Those things sometimes have
been knockout punches for us.
Total text units
over study
period
748 709 684 2141
*This is a pre-implementation construct only coded during Yr 1 interviews.
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mixed levels of organizational readiness for change, with
strong collective confidence to meet accrual goals but low
physician and hospital commitment to CBPPR. Hospitalmanagement support and resource availability were limited
across CCOP organizations early on, although they
improved in one CCOP organization. Through IPPs, all
three CCOP organizations provided high levels of research
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ever, none created formal expectations or accountability for
physicians to help the CCOP organization meet its accrual
goals. Further, all three organizations used relatively weak
IPPs to recognize and reward physicians for enrolling
patients in clinical trials. As a result, all three created a
weak implementation climate. Patient accrual became con-
centrated over time among those groups of physicians for
whom CBPPR exhibited a strong IVF. Several external
(environmental) factors also influenced innovation use,
complicating and enriching our intra-organizational model
of innovation implementation.
Below we describe our results in detail, beginning with
implementation effectiveness.
Implementation effectiveness
As an organization-level construct, implementation effect-
iveness refers to the consistency and quality of aggregate
innovation use among intended innovation users. We op-
erationally defined innovation use as patient accrual, or
the enrollment of new patients in NCI-sponsored clinical
trials. Aggregate innovation use is measured in terms of
CCOP-level patient accrual.
Figure 3 shows that CCOP A exhibited the greatest
consistency over time in total patient accrual to NCI-
sponsored clinical trials (i.e., treatment and CP/C accrual
combined). CCOP C exhibited a substantial jump in
total patient accrual in the first three years of CCOP
funding, followed by an even larger decline. CCOP B
exhibited a similar, but less pronounced pattern. All
three CCOP organizations struggled with patient accrual
in 2010 and 2011 due, in part, to external factors
(described below). Viewed somewhat differently, CCOPFigure 3 Total patient accrual by CCOP Organizations. Source: The CCO
https://ccop.nci.nih.gov/Note: Total patient accrual includes all patients enr
sponsored cancer treatment trials. CCOPs report patient accrual to the NCIA met the NCI’s accrual goals in eight of the nine
observed years for CP/C trials and six of the nine
observed years for treatment trials. CCOP C met the
NCI’s accrual goals in eight of the nine observed years
for CP/C trials, but only two of the nine years for treat-
ment trials. CCOP B met the NCI’s accrual goals in two
of the six observed years for CP/C trials and none of the
six years for treatment trials. In sum, the consistency of
aggregate innovation use was highest in CCOP A, then
CCOP C, then CCOP B.
The quality of aggregate innovation use did not vary
meaningfully across the three cases. There were minor
audit issues reported around eligibility criteria and
protocol selection in all three cases, but the data quality
and research procedures were generally robust.
The three CCOP organizations also varied in the
consistency with which physicians engaged in CBPPR.
To examine how and why this is so, we turn to our
organizational model of innovation implementation, be-
ginning with an analysis of organizational readiness for
change.
Organizational readiness for change
Success in the start-up phase of implementation
depends in large part on ORC. As noted earlier, ORC
concerns organizational members’ collective confidence
to implement change and collective commitment to
pursue courses of action that will lead to successful
change. In all three CCOP organizations, collective
confidence was high. Prior to becoming a CCOP, all
three CCOP organizations had participated in NCI-
sponsored clinical trials as research affiliates of co-
operative groups. As research affiliates, they gainedP, MBCCOP, and Research Base Management System website:
olled in NCI-sponsored cancer prevention and control trials and NCI-
on a 12-month basis from 1 June to 31 May.
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trials and used the per-case reimbursement that they
received for enrolling patients to hire research staff to
support participating physicians.
Interview participants said that, when they applied for
CCOP funding, they knew they would have to signifi-
cantly ramp up their clinical trials research operations to
meet the NCI’s accrual goals. Moreover, they acknowl-
edged some trepidation about having to enroll patients
in CP/C trials, a type of clinical research with which they
had less experience. Nonetheless, they felt confident that
they could quickly increase the scope and scale of their
research operations:
‘We were pretty confident we’d be able to meet the
treatment trials [accrual goal], if the right trials were
open. . .. The prevention [trials accrual goal] has
always been kind of an iffy in the very beginning, just
because there weren’t [large prevention] trials
available. . .. There wasn’t a SELECT [the Selenium
and Vitamin E Cancer Prevention Trial], there wasn’t
a STAR [Study of Tamoxifen and Raloxifene]. So we
thought we’d be able to meet the treatment. We never
knew about the prevention.’—CCOP B, CRA group
interview.
Although collective confidence was high, collective
commitment was more variable in all three CCOP orga-
nizations. Some physicians were committed and enthusi-
astic about becoming a CCOP organization; other
physicians were ‘supportive’ or merely ‘interested.’ In
retrospect, it is not clear whether physicians understood
that, as a CCOP, they collectively would be ‘on the hook’
for a much higher level of accrual than they were used
to generating as a research affiliate. To meet the NCI’s
expectations, physicians would have to step up their per-
sonal participation in the clinical research, enrolling
patients routinely rather than occasionally in clinical
trials. The CCOP PIs of all three CCOP organizations
succeeded in building physician support to become a
CCOP organization, but the broad support they gar-
nered did not translate into broad (or deep) commit-
ment to enrolling more patients in clinical trials after
the CCOP grant was awarded:
‘I think that they [physicians] were tolerant of it but I
don’t know that they would have independently
thought of it and I don’t know that they perceived
that to become a CCOP was going to move us to a
different level or establish a different regard for our
practice in the community. But, you know, I do think
that they heard me out and I think they were
supportive of it when they heard the reasons I felt it
was a good idea.’—CCOP B, PIIn addition, it is not clear that the CCOP PIs made the
strategic or competitive case to hospital managers for
becoming a CCOP organization (or, if they did make the
case, that hospital managers understood it). In none of
the cases did the decision to apply for CCOP funding
come from hospital managers. Instead, the PIs came up
with the idea to apply and wrote the CCOP proposal. In
one case, the PI waited until a ‘friendly’ but interim hos-
pital manager was in place before asking the hospital to
sign-off on the CCOP proposal. While the PI received
the sign-off, the stage was set for low levels of manage-
ment support once the program was funded.
In all three cases, the minimal involvement of hospital
management in the decision to apply for CCOP funding
set the stage for minimal management support once the
grant was awarded. In all three cases, managers viewed
the CCOP as a ‘doctor’s program,’ with potential benefits
or advantages for the hospital either misunderstood or
unrealized:
‘For many years here, they weren’t supportive. Then
they became supportive when they thought that it was
[good] for the hospital’s existence. So, hospital
administrators will not support programs that are for
research, and maybe that was my wrong approach
because I told them this was a research project. In
retrospect, what I should have done is said this is not
a research program, this is a quality of care
program.’—CCOP C, PI
In sum, the three CCOP PIs overestimated collective
confidence and underestimated collective commitment.
Although all three CCOP organizations met NCI’s ac-
crual goals right away, the mixed organizational readi-
ness for change exhibited in the pre-implementation
phase foreshadowed the problems that all three cases
encountered later in implementation.
Management support and resource availability
Management support matters because implementation
is resource intensive. Managers can support CBPPR by
allocating needed financial, human, and material
resources. In addition, they can shape the implementa-
tion context by communicating that CBPPR is an
organizational priority, encouraging organizational
members to implement policies and practices to support
CBPPR. Finally, managers can support implementation
by overcoming resistance to change and resolving dis-
putes over resource allocations, organizational routines,
and lines of authority.
Given the minimal involvement of hospital managers
in the decision to become a CCOP organization, man-
agement support during implementation was largely
symbolic. The managers we interviewed expressed verbal
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CBPPR as important in advancing the hospital’s strategic
goals or improving its competitive position:
‘When I attract physicians to the organization, there’s
eight or nine things that come to the top and this [the
CCOP] would probably be one of I’d say five or six, as
opposed to the first five. So, I would tell you it’s not in
my top three. I would say that when I’m talking about
attracting doctors to the organization, I’m generally
talking more at the global level.’—CCOP B, hospital
manager.
In two cases, hospital managers made no financial com-
mitment to CBPPR over the course of our study, despite
the fact that NCI funds CCOP organizations with expecta-
tions that institutional cost-sharing will occur. Instead,
managers expected the CCOP organization to ‘live on its
CCOP grant’ and any supplemental funding that physicians
generated from participating in pharmaceutical industry
trials:
‘Basically, it amounts to the CCOP grant, we get a
little bit of money from the cooperative groups and
we get the money from industry trials and the
hospital helps in the sense that they own the
foundation that gives us some philanthropic support
that helps us fill the space between what we can
generate and what our true costs are. . .they’re [the
hospital] kicking in zero dollars for every dollar that
we generate.’—CCOP A, PI
In the third case, hospital managers realized that
CBPPR had strategic value in light of the hospital’s plans
to become a major teaching affiliate of a newly opened
medical school. Three years into implementation, hos-
pital managers began making substantial financial com-
mitments to the CCOP organization, starting at one
million dollars and, later, as the Great Recession contin-
ued, reducing the amount to $800,000:
‘I think it’s evolved through the years, but I think
research has taken a greater importance. . .as that has
happened people have seen, well, you have the CCOP,
it’s been the gem, it’s been sitting there all these years
and it’s just kind of like rediscovered every year. But
now, like I said, with the medical school, the
importance of research is clearer.’—CCOP C,
physician
Although management support increased over time in
one case, the modest management support that existed in
all three CCOP organizations during start-up and early im-
plementation was, in interview participants’ minds, both ablessing and a curse. On the one hand, the CCOP
organization could ‘fly under the radar’ with little manage-
ment interference. Moreover, it was largely shielded from
the staffing reductions and budget cuts that the hospital
imposed elsewhere as the ‘Great Recession’ persisted. On
the other hand, the CCOP organization could not expand
its operations beyond what the CCOP grant could sustain.
Further, the CCOP organization could not use hospital
managers’ authority and resources to implement policies
and practices that would make physicians accountable for
helping the CCOP organization meet its accrual goals.
Implementation policies and practices
Organizations can make use of a wide variety of IPPs to
enhance organizational members’ means, motives, and op-
portunities for innovation use. IPPs are cumulative, com-
pensatory, and equifinal [15,17]. That is to say, all other
things being equal, the more IPPs an organization employs
to support innovation use the better. However, high-quality
IPPs can sometimes compensate for missing or poor-
quality IPPSs. For example, excellent in-person training
could substitute for mediocre program manuals. Finally, dif-
ferent combinations of IPPs can produce the same results.
Our analysis identified three IPP themes. First, all three
CCOP organizations provided a high level of staffing and
operational support for some, but not all, of the physicians
who wanted to enroll patients in NCI-sponsored clinical
trials. Although the specific IPPs used by the three CCOP
organizations differed somewhat (e.g., some used a mix of
registered nurses and clinical research associates while
others used only registered nurses to staff the clinical trials
program), all three provided support by screening charts
to identify potentially eligible patients, flagging charts to
prompt physicians to introduce trials to eligible patients,
educating and consenting interested patients, following
patients once enrolled in a study, and managing IRB and
other regulatory requirements. However, they could only
provide such high levels of support to those physician
practices located ‘on-site’ or in close proximity to the hos-
pitals where research staff worked. Support for ‘off-site’
physician practices was harder to provide or sustain due
to travel time and logistical difficulties. The limited sup-
port CCOP organizations could offer these physicians
contributed to uneven distribution of patient accrual.
Second, all three CCOP organizations avoided using
IPPs to create formal expectations or accountability for
physicians to help the CCOP organization meet its ac-
crual goals. The CCOP PIs and CCOP administrators
routinely cajoled, sometimes exhorted, and occasionally
begged physicians to enroll more patients in clinical
trials. They regularly provided physicians with feedback
on the CCOP organization’s accrual performance relative
to NCI’s accrual goals and usually provided physician-
level patient accrual figures. Yet, none were willing to
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patients per year that a physician had to enroll in order to
maintain membership in the CCOP organization and,
thereby, enjoy the reputational benefit of having an ‘NCI af-
filiation’:
‘This institution will not tell the referring doctors that
they can’t be members of the CCOP for some criteria.
You’ve got to put, let’s say, ten patients on a year. In
fact, the institution is going to the opposite
direction.’—CCOP C, PI
Moreover, none were willing to confront physicians
who maintained their membership in the CCOP
organization, yet consistently contributed no patient ac-
crual. Interview participants mentioned several reasons
why they were unwilling or unable to implement such
policies and practices, including not wanting to shut
anyone out who might at some point contribute accrual;
not wanting to exclude off-site physicians who received
little or no support from the CCOP organization; and
not wanting to confront colleagues who, in some cases,
were business partners:
‘No, the group has to provide support for the clinical
research program but there’s no individual
expectation that every physician will accrue ten
patients per year to clinical trials. We keep trying to
bang that drum and we provide feedback to our
doctors on a regular basis about how they are doing,
but I can’t tell that they have the requisite shame that
I would hope that they would have with some of the
numbers.’—CCOP B, PI
CCOP organizations sought to compensate for these
missing policies and practices by providing more re-
search support, but with little success.
Finally, all three CCOP organizations used relatively
weak IPPs to recognize and reward physicians for enrol-
ling patients in clinical trials. Financial incentives or
rewards were out of the question due to ethical, legal,
and regulatory concerns. So, CCOP organizations fell
back on social recognition and non-monetary rewards,
neither of which remained effective over time. Social rec-
ognition included verbal praise in meetings, certificates of
appreciation, complimentary write-ups in newsletters, and
token awards given to the highest-accruing physician.
Non-monetary rewards included paid travel to confer-
ences, batches of cookies, and other small gifts. The mo-
tivating effects of these rewards diminished over time:
‘I think that we’ve tried all the rewards that probably
many other research organizations have tried. You
know, we’ve given, boxes of candy and we’ve given giftcertificates and cookies. . .we found our doctors are
not going to enter patients on clinical trials for the
benefit of winning the chocolate chip cookies or
winning a gift certificate.’—CCOP B, PI
In sum, all CCOP organizations employed IPPs unevenly.
Although some IPPs can substitute for other IPPs, the chal-
lenges that the CCOP organizations experienced providing
support to off-site physicians and the minimal or low-
power IPPs that they used create expectations, accountabil-
ity, recognition, and rewards produced a weak implementa-
tion climate.
Implementation climate
IPPs influence innovation use through implementation cli-
mate. Organizational members ascribe meaning to the IPPs
that they experience directly or vicariously. Through ex-
perience, observation, and discussion, they develop a shared
sense of whether innovation use is expected, supported,
and rewarded. This shared sense is important when the
organizational benefits of innovation use depend on con-
sistent, high-quality use by many organizational members.
Such is the case with CBPPR in CCOP organizations. The
NCI evaluates and funds CCOP organizations based on ag-
gregate (i.e., CCOP-level) accrual.
Given the uneven IPPs that CCOP organizations put
into place, implementation climate was weak in all three
cases. None of the interview participants reported that
they were expected either by the CCOP organization or
by hospital management to enroll any particular number
of patients in clinical trials each year to maintain mem-
bership in the CCOP organization. Likewise, none
reported that they were recognized or rewarded in a
meaningful way for helping the CCOP organization meet
its accrual goals. Physicians practicing in or near the
hospital felt supported by the CCOP to enroll patients in
clinical trials; off-site physicians did not.
Although implementation climate was weak in all
three CCOP organizations, all three nonetheless met or
exceeded NCI’s accrual goals. To understand how the
CCOP organizations achieved this feat, we must exam-
ine the pattern of IVF among physician groups.
Innovation-values fit
As noted above, IVF refers to the extent to which
organizational members perceive that innovation use
will foster the fulfillment of their values. Values are con-
cepts or beliefs that pertain to desirable end states or
behaviors. Although individuals can hold different
values, so too can groups. Different physician groups, for
example, may hold different beliefs about clinical trials
participation. Individuals and groups can also differ in
the amount of feeling they attach to a concept or a be-
lief. Clinical trials participation might be valued strongly
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and considered desirable, but not necessary.
When implementation climate is weak, innovation use
depends primarily on IVF. Individuals and groups that
strongly value CBPPR will enroll patients in clinical trials
even if they perceive little expectation or extrinsic re-
ward for doing so, provided adequate support exists. If
inadequate support exists, ‘true believers’ will find it dif-
ficult to enroll patients on a consistent basis, leading
perhaps to frustration and disappointment. By contrast,
individuals and groups that do not strongly value CBPPR
will enroll few patients, if any, because they see little rea-
son to do so when enrolling patients is neither expected,
nor supported, nor rewarded.
We observed individual differences in IVF in all three
cases. Not surprisingly, the CCOP PIs highly valued
CBPPR and enrolled many patients. In one CCOP
organization, a physician enrolled many patients in
pharmaceutical industry trials but relatively few in NCI-
sponsored clinical trials. Industry trials exhibited a
greater fit with his high-intensity values because, in his
view, they gave him access to newer, more exciting
drugs. In another CCOP organization, a physician stated
that he did not like the NCI’s treatment trials because
they were not, in his view, always addressing important
scientific questions; however, he was willing to help the
CCOP organization achieve its accrual goals by enrolling
patients in cancer control trials.
We also observed group-level differences in IVF in all
three cases. Medical oncologists as a group more
strongly valued CBPPR, and therefore enrolled more
patients in NCI-sponsored clinical trials, than did radi-
ation oncologists or other physician groups. Interview
participants in two CCOP organizations noted that radi-
ation oncologists as a group were ‘supportive,’ but not
‘committed’ to enrolling patients in NCI-sponsored clin-
ical trials. The radiation oncologists would follow the
clinical trial protocol for those patients that the medical
oncologists enrolled, but they would not enroll patients
in radiation-therapy clinical trials in sufficient numbers
to help the CCOP organization meet its accrual goals:
‘The total again is 8% of the patients. So that means
they put eight, nine, ten patients on this whole
year. . .I’ve been here for 20 years and this is pretty
typical for the way the radiation therapists have
performed over the last 20 years. This is nothing
different. They just don’t do a lot of randomized, you
know, Phase III trials, which is what we do as a
CCOP. They do a lot of Phase II trials.’—CCOP C, PI
Even when provided with additional research staff sup-
port, radiation oncologists as a group would not contrib-
ute much on a consistent basis. CBPPR was simply not ahigh-intensity value for them, interview participants
said.
In a third case, radiation oncologists as a group strongly
valued CBPPR, as evidenced by their active in-house re-
search program. However, they preferred to enroll patients
in in-house studies rather than NCI-sponsored clinical
trials because such studies were more instrumental in ful-
filling their values (i.e., they felt such studies were more
interesting and easier to do).
Given weak implementation climate and variable IVF, all
three CCOP organizations exhibited inconsistent, uneven
distribution of patient accrual among individuals and
groups of physicians. Of the three cases, CCOP A exhibited
the strongest IVF among medical oncologists as a group.
This CCOP organization recruited and hired physicians
who valued CBPPR, and it reinforced CBPPR as a group
value in a variety of formal and informal ways. Reflecting a
more distributed (or even) pattern of patient accrual, the PI
of CCOP A enrolled on average only 28% of the patients
per year that CCOP A accrued to NCI-sponsored clinical
trials from 2002 to 2010. By comparison, accrual was more
concentrated at CCOP C and CCOP B. In the former case,
the average annual accrual contribution of the PI was 34%,
while in the latter case it was 44%. At start-up, CCOP C
exhibited more evenly distributed accrual among physi-
cians, with the CCOP PI accounting for only 18% of patient
accrual in the first year. With off-site physicians receiving
little support, and radiation oncologists focused on in-
house studies, initial enthusiasm faded and accrual become
increasingly concentrated among the few ‘true believers.’ By
2008, six years after start-up, the CCOP PI’s contribution
accounted for over 42% of total patient accrual. In CCOP
B, the concentration of patient accrual was high at start-up
and increased steadily over time. In the first year, the PI’s
contribution accounted for 39% of total patient accrual. By
2009, it amounted to 59%, despite personal appeals from
the highly regarded PI and increased research support for
low- or non-accruing physicians. An interview participant
described the situation:
‘And our accruals here are actually up but once again,
we’re really concerned that [the CCOP PI] has [put]
40 some odd patients on treatment trials. Everyone
else in the CCOP is at single digits. And we don’t
know, we’re getting ready to have a discussion with
the other physicians and [the PI] and I are mulling
things over on how to present this but this can’t go
on. It just can’t go on. If you want us to maintain
ourselves as a viable CCOP, everybody’s got to pull
their weight.’ –CCOP B, CCOP Administrator
External factors
Although the organizational model of innovation imple-
mentation used in this study focused our attention on
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that CCOP organizations are heavily dependent on two ex-
ternal resources needed for CBPPR—trials and patients. In
varying degrees, all three CCOP organizations experienced
difficulties obtaining these resources, which, in turn, exacer-
bated the challenges posed by a weak implementation
climate and variable IVF.
Interview participants noted that the menu of NCI-
sponsored clinical trials available to CCOP organizations
has shrunk in the past two years and contains significant
gaps in common disease areas, such as colon cancer.
Interview participants attributed the trial availability
problem to the consolidation of the cooperative group
system that is currently taking place in response to an
influential, yet critical report by the Institute of Medicine
[25], a not-for-profit, non-governmental organization
that advises the federal government on issues related to
biomedical science, medicine, and health. With fewer
treatment trials available, CCOP organizations are strug-
gling to meet their treatment trial accrual goals. In
addition, with no large cancer prevention trials available,
CCOP organizations are trying to meet their CP/C ac-
crual goals through symptom management trials. These
smaller trials often close quickly to new patient accrual,
disadvantaging those CCOP organizations (like CCOP
C) that work with slow IRBs, which must approve stud-
ies locally before CCOP organizations can enroll patients
in them.
Interview participants further noted that NCI-
sponsored clinical trials are increasingly testing targeted
therapies applicable only to small subgroups of cancer
patients. Not long ago, breast cancer treatment trials
would open to almost any patient with, say, advanced
disease and no co-morbidities. Today, trials are testing
different therapies for node positive and negative breast
cancer, which can be further divided into pre- and post-
menopausal categories, which can be further sub-divided
into other categories, creating approximately 16 different
groups of breast cancer patients. Similar trends are oc-
curring in treatment trials for other cancers. Interview
participants referred to this as a ‘needle in a haystack’
problem:
‘What’s happening is [that] what used to be gigantic
baskets of patients are [now] being divided up by
biology. It’s better medicine to divide them. . .. Each
one of these breast cancers is a bit different, [and]
each one of them has a different [treatment] protocol.
So now. . .I just cut breast cancer into 16 different
groups. . .. And I think that accounts for a large
degree why we don’t really have any rainmaker
studies.’—CCOP A, PI
To meet their accrual goals, some interview partici-
pants observed, they cannot afford to miss anyopportunity to enroll an eligible patient. Hence, they feel
frustrated when low- or non-accruing physicians let an
eligible patient go un-approached.
Finally, interview participants commented that meeting
the NCI’s expectations for patient accrual became increas-
ingly difficult in the face of persistent economic recession
and increased market competition. Midwestern states,
where the three COCP organizations operate, have been hit
especially hard. Patient volume has declined across the
board as patients put off medical care to manage other liv-
ing expenses. Interview participants noted that patients
have voiced more concern about enrolling in a clinical trial
because they are worried about their health insurance
coverage and out-of-pocket costs. Given job insecurity,
patients are more reluctant to take time off work to receive
multiple rounds of cancer treatment and return for follow-
up clinical visits. At the same time, local market competi-
tion has grown. The PI of CCOP A noted, for example, that
he and his four partners were the only medical oncologists
in town in the first year of the CCOP grant. Now, he has
eight partners and there are two competing oncology prac-
tices not affiliated with the CCOP organization that have
seven more medical oncologists. The number of cancer
patients has not increased threefold over time.
Discussion
CBPPR is a promising strategy for translating research
results into clinical practice. By engaging providers in
the research process, researchers can gain insight into
the clinical issues in community practice settings, obtain
provider input on study design and implementation con-
cerns, and discover the tacit practice-based knowledge
that exists in community practice settings. By doing re-
search in their own practice settings, providers may feel
a greater sense of ownership and trust in clinical re-
search results, which, in turn, may increase their com-
mitment to acting on research findings. Yet, CBPPR
does not occur spontaneously or effortlessly. To partici-
pate in research, community-based providers often must
implement systemic changes in organizational staffing,
office workflow, information systems, and reward struc-
tures. In addition, they must develop an organizational
culture (shared values) that supports CBPPR and
evidence-based practice.
Our study findings contribute to the limited body of
research on the implementation of CBPPR. Three find-
ings in particular have policy and practice implications
that merit discussion. First, CBPPR is difficult to create
and sustain in the absence of management support from
local, affiliated hospitals and health systems. Managers
not only control critical institutional resources, but play
(or could play) an important role in legitimizing the
value of CBPPR, authorizing policies and practices to
support CBPPR implementation, and addressing turf
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policy standpoint, the NIH and other federal agencies
seeking to increase CBPPR should require hospital and
health system executives to make tangible institutional
commitments in order to participate in federally funded
provider based research networks or other programs. In
its National Community Cancer Centers Program, the
NCI went a step further by engaging the chief executive
officers of participating hospitals and health systems as a
stakeholder group, inviting them to national program
meetings, recognizing their participation publicly, and
creating opportunities for them to meet privately as a
group with the NCI Director [26]. From a practical
standpoint, community-based providers need to make
the strategic or business case for CBPPR by showing
hospital and health system executives how participating
in clinical research aligns with and advances
organizational priorities. It might be useful to frame
CBPPR as ‘quality enhancement’ rather than ‘research,’
as the CCOP PI did in the one case we observed where
hospital managers made a significant financial commit-
ment to CBPPR. Newly available tools for assessing the
business case could also prove useful [27].
Second, community-based providers face demanding
schedules and heavy workloads and, thus, need substan-
tial staff support to participate in clinical research.
CCOP organizations struggled to provide adequate staff
support to physicians who practiced in locations more
than a few miles from the hospital or physician office
buildings where research staff were based. Even high-
accruing physicians found it difficult to enroll patients in
clinical trials when they traveled to outlying rural clinics.
The policy implication is that the NIH and other federal
agencies seeking to promote CBPPR should be prepared
to provide adequate, consistent funding to create and
maintain the research infrastructure necessary to sup-
port CBPPR. To its credit, the NCI uses peer-reviewed
cooperative agreements to award multi-year grant fund-
ing directly to CCOP organizations, rather than passing
the money through academic medical centers or other
intermediaries [12]. Direct funding puts more resources
in the hands of community-based providers who want to
engage in clinical research. Multi-year funding offers
predictability and stability for longer-term planning, or-
ganizing, and staffing. Cooperative agreements permit
local flexibility in resource allocation, while ensuring
regular performance monitoring and financial reporting.
From a practical standpoint, community-based providers
could stretch the resources they have for CBPPR by
experimenting with decentralized research staffing mod-
els, having a research staff member accompany traveling
physicians, training office staff members to assist with
research tasks, using information and communications
technologies to support providers’ participation inresearch, and triaging research staff to support those
‘off-site’ providers with the greatest potential for and
likelihood of increased research participation.
Finally, research infrastructure is necessary, but not
sufficient to gain providers’ commitment to CBPPR. Al-
though CCOP organizations were able to provide high
levels of staff support to at least some CCOP physicians,
they did not succeed in creating a shared sense among
CCOP physicians that enrolling patients in clinical trials
was expected, supported, and rewarded. Given a weak
implementation climate and variable degrees of IVF, all
three CCOP organizations exhibited inconsistent, un-
even distribution of patient accrual among individuals
and groups of physicians. Implementation climate is
more amenable to policy and practice intervention than
IVF [16,17]. At the policy level, the NIH, other federal
agencies, and professional associations could stimulate
demand for CBPPR by launching a national public ser-
vice advertising campaign to encourage patients to par-
ticipate in clinical research [25]. Increased patient
demand could increase clinicians’ sense that CBPPR is
expected. Further, these parties could do more to pro-
vide public recognition of clinicians who engage in
CBPPR. On a practical note, community-based providers
should consider establishing formal expectations and
accountability procedures to strengthen the implementa-
tion climate for CBPPR [25]. The Delaware Christiana
CCOP organization did so in 2008 [28] and later
reported that CCOP accrual increased, despite one phy-
sician’s resignation from the CCOP organization [29]. In
2011, two of the three CCOP organizations we studied
followed Delaware Christiana’s example. It is too soon to
tell what results they achieved.
The organizational model of innovation implementation
employed in this study proved useful for investigating the
organizational factors that facilitated and hindered start-
up and early implementation of CBPPR in CCOP organi-
zations. However, study findings results suggest two ways
in which the model could be refined. First, the model’s
focus on intra-organizational factors obscures the extent
to which extra-organizational factors influence innovation
implementation within organizations. Community-based
providers are heavily dependent on external resources and
subject to many legal, regulatory, and professional con-
straints. While these external factors may influence
innovation implementation through intra-organizational
factors identified in the theory (e.g., by shaping manage-
ment support, resource availability, and IPPs), they could
also directly influence innovation use. CCOP organiza-
tions, for example, cannot modify the protocols of NCI-
sponsored clinical trials once the trials become open for
patient accrual. CCOP organizations can decide not to
make use of trials that do not fit local patient populations,
practice patterns, or organizational resources. Doing so,
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accrual. External factors may also change the conceptual
meaning of intra-organizational factors. For CCOP organi-
zations, for example, resource availability includes both
organizational slack—that is, unused and potentially avail-
able financial resources from hospitals [15,30-32]—as well
as CCOP grant funding.
Second, we described IPPs as cumulative, compensa-
tory, and equifinal. Specifically, following Klein et al.
[15,17], we argue that the presence of some high-quality
IPPs may compensate for the absence or low quality of
other IPPs. Although we found some support for this
idea, our results suggest there are limits to IPPs’ substi-
tutability. Providing more research support to low- or
non-accruing physicians, for example, did not compen-
sate for missing or weak IPPs concerning expectations,
accountability, recognition, or rewards. Organizational
members must have not only the means to achieve con-
sistent, high-quality innovation use, but also the motives
and the opportunity to do so. It may be the case that
IPPs can compensate or substitute for one another
within the categories of means, motives, and opportun-
ities, but not perhaps across these categories.
Study limitations
All studies have limitations. Ours is no exception. Case
study research emphasizes depth over breadth, insight
over generality [20-22]. Three cases, no matter how
closely studied, do not provide a sufficient basis for statis-
tical generalization. To help others assess the reasonable-
ness of applying our findings to other practice-based
research networks (PBRN), we offer a ‘proximal similarity
model’ [33] that suggests two important gradients along
which PBRNs vary: the type of clinical research conducted
by the PBRN, and the strength of the science upon which
it is based; and the level of federal support provided to the
PBRN. The more proximal a PBRN is to the CCOP on
these gradients, the greater the reasonableness of applying
study findings beyond the specific people, places, settings,
and times from which they were generated. With this
proximal similarity model in mind, two factors increase
our confidence in the transferability of our study findings.
First, the CCOP has already served as a model for other
federally supported PBRNs [34], and the NIH continues to
look to the CCOP for guidance as it implements the Road-
map. Second, a recent survey found that many clinical
research networks funded by the NIH share with the
CCOP key organizational features with respect to funding,
design, and operation [35]. This means that many NIH-
funded clinical research networks are proximally similar
to the CCOP.
As is true of all research, case study research involves an
irreducible element of expert judgment. We employed sev-
eral case study research tactics to increase the dependabilityand credibility of our study results, including the use of the-
ory to conceptually and operationally define constructs; use
of multiple sources of data; use of experienced interviewers;
use of a common interview guide and codebook; audio-
recording and transcription of interviews; use of software
to code transcripts and document coding decisions; and
duplicate coding and systematic review of coded tran-
scripts, summary reports, and meta-reports by multiple
research team members. We feel confident in our use of
these time-honored case study research tactics, but we can-
not discount fully the possibility that investigator bias in
interpretation influenced our results.
Conclusion
In conclusion, a small, but growing body of research indi-
cates that community-based providers who engage in
clinical research more rapidly adopt evidence-based clinical
services than those who do not engage in clinical research
[36-41]. These studies suggest that CBPPR holds promise
as a strategy for accelerating the translation of research
results into clinical practice. Our results contribute to the
limited body of research on the implementation of
community-based provider participation in research. They
inform policy discussions about increasing and sustaining
community clinician involvement in clinical research and
expand on theory about organizational determinants of im-
plementation effectiveness.
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